Favorable Press Coverage Somewhat Unlikely to Impact Corvus Pharmaceuticals (CRVS) Stock Price
News articles about Corvus Pharmaceuticals (NASDAQ:CRVS) have trended positive this week, Accern Sentiment reports. The research firm identifies positive and negative press coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Corvus Pharmaceuticals earned a news impact score of 0.30 on Accern’s scale. Accern also gave headlines about the company an impact score of 47.5395348626128 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
Several analysts recently weighed in on the company. Zacks Investment Research upgraded Corvus Pharmaceuticals from a “hold” rating to a “buy” rating and set a $16.00 target price for the company in a research note on Tuesday, November 7th. Wedbush restated an “outperform” rating and set a $26.00 target price on shares of Corvus Pharmaceuticals in a research note on Tuesday, August 8th. Finally, Credit Suisse Group upgraded Corvus Pharmaceuticals from an “underperform” rating to a “neutral” rating and set a $14.00 target price for the company in a research note on Wednesday, August 23rd. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $20.25.
Shares of Corvus Pharmaceuticals (CRVS) traded down $0.13 during trading hours on Monday, reaching $12.79. The company had a trading volume of 29,900 shares, compared to its average volume of 107,786. Corvus Pharmaceuticals has a 1 year low of $8.27 and a 1 year high of $22.14.
Corvus Pharmaceuticals (NASDAQ:CRVS) last announced its earnings results on Thursday, November 2nd. The company reported ($0.62) earnings per share for the quarter, beating the consensus estimate of ($0.81) by $0.19. equities analysts forecast that Corvus Pharmaceuticals will post -2.82 earnings per share for the current year.
Corvus Pharmaceuticals Company Profile
Corvus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology therapies. The Company is developing drugs and antibodies that block crucial immune checkpoints and reprogram immune T-cells. The Company has a pipeline of four immuno-oncology programs, three of which focus on the adenosine-cancer axis to modulate an immune response.
Receive News & Ratings for Corvus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corvus Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.